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Background: When a patient is admitted to the hospital he or she should be screened for 
malnutrition within the first 24 hours. If the patient is identified as being at risk, appropriate 
treatment should be given, and then the patient receives the appropriate ICD-10 code for 
malnutrition at discharge. This tells us that malnutrition has been treated, and should ensure 
that the ward receives reimbursement for the treatment given. The Norwegian health 
authorities gave the recommendations for prevention and treatment of hospital malnutrition in 
2009, but are these guidelines being followed in clinical practice?  
Malnutrition is present in 19% - 60% of hospitalized patients, depending on the population 
under study and the screening tools used. Malnutrition is known to increase morbidity and 
length of stay (LOS), and therefore result in increased health care and hospital costs.  
It is estimated that it is possible to save an annual amount of 800 million Norwegian kroner, 
by identifying and treating malnutrition in Norwegian hospitals.  
Aims: The aim of this study was to evaluate the screening routines and nutritional treatment 
given at a haematology ward in a Norwegian university hospital, to evaluate if better routines 
can have an economic impact based on identification and coding for malnutrition, length of 
stay, and nutritional treatment.  
Methods: The thesis had a retrospective part where the above mentioned outcomes were 
studied, and a prospective part to evaluate the impacts of an intervention consisting of an 
instructive course. The routines for nutritional screening and treatment were evaluated by 
collecting data from the electronic medical record. The intervention was aimed towards the 
nurses. They received guidance and lectures on screening and nutritional treatment. 
Results: Medical records of 302 patients were retrospectively evaluated during two periods. 
137 patients in the first period, and 165 patients in the second. In the first period no patients 
were screened for malnutrition, while 15 (9%) were screened in the second period (p < 0.001). 
There was not a significant difference in routines for coding malnutrition (8 in the first, 12 in 
second. P-value = 0, 651), and hence no difference in potential reimbursement. A significant 
decrease in LOS was observed, from a median of 5 to 4 days (p = 0,015), which was 
estimated to give a potential reduction of costs equivalent to NOK 7 289 350.00 annually. 
There was no significant difference in patients receiving nutritional treatment, individual 
nutritional plan or referral to clinical dietician. At the same time there was no significant 
difference in the kind of nutritional treatment given (parenteral nutrition, enteral nutrition, and 
oral nutritional supplements). 
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Conclusions: An intervention consisting of an instructive course, with relevant lectures and 
training nurses in screening, resulted in a significant increase of screened patients. The 
intervention had no impact on routines for the coding of malnutrition, and the diagnosis 
related group (DRG) reimbursement for malnutrition. LOS was reduced, and this could 
potentially result in reduced costs. Our study indicates that the routines for nutritional 
screening are deficient, and that there is still room for improvement of nutritional routines at 
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1.1 Haematological malignancies 
Haematological malignancies are a group of different conditions, which originate from the 
cells of the bone marrow and the lymphatic system. These malignancies can be divided into 
myeloid or lymphoid processes, according to the cell-line involved. They can in addition be 
classified as being acute or chronic depending upon the maturation phase of the cell in which 
the malignant transformation occurs (1, 2). The myeloid malignancies usually originate from 
the bone marrow progenitors that are restricted to developing into erythrocytes, granulocytes 
(neutrophils, basophils, and eosinophils), monocytes and megakaryocytes. The exception is 
chronic myeloid leukaemia (CML), where the cell of origin is a pluripotent haematopoietic 
stem cell capable of giving rise to lymphoid cells as well (3). This could be exemplified by 
the arise of acute lymphoblastic leukaemia (ALL) with Philadelphia chromosome, the same 
chromosomal change seen in CML. These malignancies include three broad clinicopathologic 
categories: acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), and 
myeloproliferative neoplasms (MPN). There is also a overlap category MDS/MPN, for 
patients who present with features of both MDS and MPN (3, 4). Lymphoid malignancies are 
derived from cells that normally develop into T lymphocytes (cytotoxic T lymphocytes, 
helper T lymphocytes, or regulatory T lymphocytes) or B lymphocytes (lymphocytes or 
plasma cells). The lymphoid malignancies are divided according to the maturity of the 
lymphoid precursors, and they are further grouped depending upon whether they are of B or T 
cell derivation (3). Worldwide, more than 250 000 people are diagnosed with leukaemia each 
year. All age groups can be affected, but most cases occur in older adults; more than half after 
65 years of age. The incidence rates for all types of leukaemia are slightly higher among 
males than among females (1). In Norway leukaemia is one of the 10 most common types of 
cancer in the period 2010 – 2014. Leukaemia accounts for 4 % of the male cancer incidence, 







Figure 1. Classification of haematological malignancies 
AML = acute myeloid leukemia; CML = chronic myeloid leikeamia; MDS = myelodysplastic syndrome; 
MPN = myeloproliferative neoplasms; ALL = acute lymphoblastic leukaemia; CLL = chronic 





1.2 Treatment of haematological malignancies 
The approach of treatment depends on the type and severity of the disease. It ranges from 
observation of asymptomatic patients, supportive care with blood transfusion and venesectio, 
to corticosteroids, radiotherapy, combination chemotherapy and hematopoietic cell 
transplantation (HCT) (2). Acute leukaemia requires immediate treatment to induce 
remission. This first phase of therapy includes high dose intensive combination chemotherapy 
to reduce or eradicate leukemic cells from the bone marrow and re-establish normal 
haematopoiesis (2). HCT is recommended for selected adult patients, to prevent relapse of the 
disease (2, 6). HCT is a wide description of treatments where hematopoietic cells are 
intravenously infused with the intention to establish marrow and immune function, mainly in 
patients with haematological malignancies  (2, 7). These treatments are used in the hope of 
curing or substantially prolonging remission, but they also have severe side effects (2).  In 
autologous HCT the patient´s own stem cells are harvested and used to repopulate the bone 















MM and variants 
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transplantation (HSCT) uses HCT from a human leucocyte antigen (HLA) matching sibling 
donor or volunteer unrelated donor  (2, 6). The treatments are initiated with a conditioning 
therapy (chemotherapy ± radiotherapy) before the transplantation to help eradicate the 
malignant disease and to cause immunosuppression. This also reduces the risk of marrow 
rejection in the case of allogenic HSCT. The stem cells are then infused to prevent bone 
marrow failure (2). The transplanted immune system in allogenic HSCT have a strong anti-
leukemic effect, the so-called graft versus leukaemia effect exerted by donor T cells, and this 
is the major way it eliminates the malignant disease. However, the alloreactive T cells can 
also harm healthy tissues, a complication known as graft-versus-host-disease (GVHD), which 
might predispose patients to treatment-related mortality (2, 6, 9). A known side effect due to 
this intensive treatment is an increased risk for malnutrition (10, 11).  
 
 
1.3 Nutritional aspects  
 
1.3.1 Malnutrition 
Malnutrition can be a result of starvation, disease or aging. It has been defined as “a state 
resulting from a lack of uptake or intake of nutrition leading to altered body composition 
(decreased fat free mass) and body cell mass leading to diminished physical and mental 
function and impaired clinical outcome from disease” (12). Although the term can be said to 
refer both to over- and under-nourished individuals, it is often used synonymously with 
undernutrition, and this is also the case in this thesis (12). Malnutrition is associated with 
reduced quality of life, a lower activity level, increased treatment-related adverse reactions in 
cancer patients, and reduced tumor response to treatment, in addition to reduced survival. 




Malnutrition is present in 19% - 60% of hospitalized patients, depending on the population 
under study and the screening tools used (14-16). Not only is malnutrition prevalent in 
hospitals, but it is also a common feature in the community and in care homes. A study with 
401 oncology patients in Spanish hospitals showed that 33.9% patients were at nutritional risk 
according to Nutritional Risk Screening (NRS 2002) at admission, and 36.4% in risk at 
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discharge. The haematology department had one of the highest prevalence of patients in 
nutritional risk (46.2%). In patients with haematological neoplasms the prevalence of 
nutritional risk at admission was 36.8%, and 51.6% at discharge (17). At Haukeland 
University Hospital in Norway, the overall prevalence of nutritional risk was 29%. Looking 
further prevalence in hospital departments and units, the highest prevalence were in intensive 
care (74%), oncology (49%) and pulmonology (43%) (18).  
 
 
1.3.3. Associated Causes  
Hospital malnutrition is multifactorial, and associated with type and severity of disease, high 
age and poor food intake (15). A greater risk of nutritional decline in medical patients may 
also be associated with a low BMI at admission, simultaneous illnesses and infection, reduced 
food intake and a perceived low food quality and presence of illness affecting food intake 
(19). Norwegian studies based on point prevalence surveys found that nutritional risk also is 
present in younger patients and overweight patients (18). In a group of oncology patients with 
lung cancer, concurrent radiotherapy and chemotherapy, advanced-stage tumours and tumour 
size were independently associated with weight loss ≥5% (20). HSCT is associated with 
severe gastro toxicity and symptoms which may compromise food intake. Treatment with 
high dose chemotherapy can cause severe vomiting and lead to mucositis the gastrointestinal 
tract. Taste and smell perception is altered, and use of narcotic analgesics can lead to 
intestinal dysmotility. Diarrhoea caused by loss of functioning intestinal epithelium, leads to 
malabsorption (21, 22). All these factors can contribute to a reduced food intake as well as 
reduced uptake of nutrients, resulting in risk of malnutrition. The two types of HSCT 
treatments can affect nutritional status to different extents. Both receive high-dose 
chemotherapy, but patients receiving autologous transplantation have a reduced time to 
engraftment, duration of neutropenia, and as a result, a reduced duration of neutropenic 
mucositis. Unless severe complications occur, sufficient oral food intake can be frequent in 
these patients (23). The total-body irradiation to induce immunodepression in patients 
receiving allogenic transplantation, induce a more severe and prolonged mucositis. In 
addition, the patient could not respond to immunosupptrssive therapy, and develop acute 
GVHD, resulting in severe diarrhoea and abdominal pain. These, among other factors, can 
futher contribute to the development of malnutrition (23).  
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1.3.4 Dealing with hospital malnutrition 
With a high prevalence of malnutrition in hospitals, and several associated causes there is 
need for a way of identifying the patients in risk of malnutrition in order to give nutritional 
treatment to the right patients. Screening tools have been developed for use in different 
settings (24, 25). These are designed to be rapid and easy to use by busy nurses and other 
medical staff in a community setting or in hospitals. They usually involve an assessment of 
weight and height, food and fluid intake, and duration of health status (26). Routine screening 
of patients to identify risk of malnutrition has been recommended by many national, 
international and specialist organisations (26-28). The European Society for Parenteral and 
Enteral Nutrition (ESPEN) recommends the use of the NRS-2002 for hospitalised patients 
(26). When being identified as being in risk, the next step is to give nutritional treatment. It is 
recommended that an estimate of energy and protein requirements, as well as a prescription of 
food, oral supplements, tube feeding, parenteral nutrition or a combination of these, should be 
documented in a nutritional care plan (26). 
 
 
1.3.4 Enteral and parenteral nutritional therapy 
One way of increasing energy intake in malnourished patients with a reduced energy intake, is 
to give enteral nutrition (EN) by means of oral nutritional supplements (ONS) and tube 
feeding (TF) (13). In a hospital setting TF is often referred to as EN, and this is also the case 
here.  It is recommended that ONS or EN should be started if malnutrition already exists or if 
the food intake is markedly reduced for more than 7-10 days (13).  EN is usually preferred to 
parenteral nutrition (PN), as EN has fewer complications, has better outcomes and is also the 
cheaper alternative (29, 30). The ESPEN (European Sosciety of Parenteral and Enteral 
Nutrition) guidelines concluded however that routine use of EN was not recommended for 
patients undergoing HCT. Further they comment that parenteral nutrition (PN) may be 
preferred to EN in situations where there might be a risk of complications with enteral tube 
placement, like increased risk of haemorrhage an infections in immuno-compromised and 
thrombocytopenic patients (13). These statements are both grade C recommendations, 
meaning that the evidence is based on expert opinions and/or clinical experience of respected 
authorities, including the view of the working group (31). However, the A.S.P.E.N. 
(American Sosciety of Parenteral and Enteral Nutrition) guidelines report that EN is safe as a 
transition step from PN to oral diet, to patients undergoing HCT, when neutrophil and platelet 
counts have returned and gastrointestinal tissues have healed. When PN is used, it should be 
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discontinued after stem cell engraftment when it is possible to achieve an adequate intake by 
EN or orally (32).  
 
 
1.4 Haukeland University hospital 
 
1.4.1 Haematology ward 
The haematology ward at the university hospital treats and examines inpatients with 
haematological diseases, in addition to some general medicine. The most common diseases 
are acute leukaemias, multiple myeloma (MM), myelodysplastic syndrome (MDS), deep 
venous thrombosis (DVT) and pulmonary embolism, aplastic anaemia, Waldenström’s 
macroglobulinemia, hairy cell leukaemia and other rarer haematological diseases. Other 
patients are admitted if there is extra capacity. The ward has 16 beds; two 4-bed rooms, one-
day treatment room, and seven single rooms. Three of the single rooms are overpressure 
isolates with HEPA filters. The staff consists of nurses, oncology nurses, nursing assistants, 
postal secretary and eight haematologists, two of which are professors and doctors in training. 
They also have a physiotherapist present at the ward on a daily basis, and they have the 
opportunity to have a social worker and a pharmacist present when needed anomg others, as 
well as clinical dieticians. The ward performs autologous stem cell transplantation, and serves 
as a regional/national institution for allogenic stem cell transplantation (33).  
 
 
1.4.2 The Haukeland University Hospital’s nutritional strategy 
In 2006 Haukeland University Hospital introduced a nutritional strategy, with guidelines to 
improve routines for prevention and treatment of disease related malnutrition. This strategy 
was focused towards adult, inpatients in somatic medicine. The vision was described as: 
“Optimal nutrition for all patients, “and initiatives were described as follows: 
1) Improve food availability 
2) Improve knowledge 
3) Improve nutritional treatment 
4) Document the effect of the initiatives 
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Guidelines implemented in 2007 gave clear recommendations that all patients admitted at the 
hospital should be screened for malnutrition with the validated screening tool Nutritional Risk 
Screening (NRS) 2002 (26). The patients in nutritional risk shall receive an appropriate 
nutritional treatment based on an evaluation and a collaboration between physicians, nurses, 
and clinical dieticians (34). Other measures described in the nutritional strategy were 
interactive tools like website, electronic learning course in clinical nutrition and dedicated 
forms for screening and nutritional plan in the electronic patient journal system (appendix 1. 
and 2.). Another important part was to increase flexibility of food services by opening dining 
areas for patients near the wards, with a buffet and kitchen personnel who could customize 
and improve the serving. Clearly defining responsibilities in planning and managing 
nutritional care is recognized as important for proper nutritional care in hospitals (28). The 
nutritional strategy defines that nurses are responsible for screening the patients, and the 
physicians are responsible for starting nutritional treatment and document the appropriate 
ICD-10 code for malnutrition. Both nurses and physicians can contact clinical dieticians if 
patients require additional nutritional assessment and expertise (34).   
 
1.4.3 Point prevalence surveys 
To evaluate the effect of the implemented nutritional strategy, point prevalence surveys are 
conducted 3-4 times a year. All eligible patients are screened for malnutrition according to 
NRS 2002, and this information as well as information about nutritional treatment is 
registered in a separate registration programme by each of the participating departments.   
These point prevalence surveys identify malnutrition as a risk factor with disease in the whole 
hospital population as well as each of the hospitals departments. The final results are available 
for all employees at Haukeland University Hospital on their intranet. These results are to be 
considered as raw data, as they have not been further evaluated and processed. A PhD thesis 
has been conducted based on data from the point prevalence surveys from 2008 to 2009. 
These data showed that 34% of the hospitalized patients were at nutritional risk. Further it 
was estimated that 70% of the eligible patients (adult patients) were screened, 53% of the at 
risk patients received nutritional treatment and only 5% were seen by a dietician (35). The last 




Figure 2. Overview of point prevalence surveys conducted at Haukeland university hospital from 2009 
to 2015.  
1. % nutritional risk is defined as the number of patients with a score ≤ 3 according to NRS 2002, of 
the number of patients screened.  
2. % screened is defined as number of patients screened of the total number of patients admitted at 
the departments.  
3. % of patients in risk who received treatment is defined as the number of patients receiving 
nutritional treatment of the patients in risk.  
 
The point prevalence surveys showed that on average 74% of the patients were screened. 
Average nutritional risk of the screened patients from 2009-2015 was estimated to be 25%, 













Point prevalence surveys Haukeland University Hospital 
2009 - 2015 
 
1 % nutritional risk of screened patients
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Figure 3. Overview of point prevalence surveys at the haematology ward from 2009 to 2015.  
1. % nutritional risk is defined as the number of patients with a score ≤ 3 according to NRS 2002, of 
the number of patients screened.  
2. % screened is defined as number of patients screened of the total number of patients admitted at 
the departments.  
3. % of patients in risk who received treatment is defined as the number of patients receiving 
nutritional treatment of the patients in risk.  
 
Based on the point prevalence surveys, 89 % of the eligible patients at the ward were 
screened. Average risk of malnutrition in the screened patients from 2009 to 2015 was 70%, 
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1.5 Economical aspects 
To derive the greatest benefits from the available recourses in the health services it is 
necessary to perform some form of economical evaluation. The economical evaluation 
assesses the efficiency and use of recourses that may improve health care and health 
outcomes. We want to estimate the relationship between costs related to a given measure and 
the effects of these measures (36). There are different ways of evaluating this. A cost analysis 
compares net costs of different strategies with the same outcome on a patient or population 
level. A cost-benefit analysis compares the costs of implementing strategies with different 
units of outcome and says something about net health benefit or net monetary benefit at 
patient or population level. Cost-utility analysis compares implementation strategies that have 
morbidity and mortality outcomes and gives the cost per quality adjusted life year. A cost-
effectiveness analysis compares implementation strategies that produces a common outcome 
measured in a cost-effectiveness ratio (36).  
 
1.5.1 Economic costs of hospital malnutrition  
Malnutrition among hospitalized patients has been known to increase morbidity and mortality, 
hospitalization rates and LOS, and result in increased hospitalization costs (37-39). A review 
from 2015 found that economic costs of hospital malnutrition in Europe lead to an increased 
LOS ranging from 2.4 to 7.2 days, and that malnutrition led to an additional individual cost 
ranging between 1640 EUR to 5829 EUR (NOK 15 336 – NOK 54 510) (kurs 9,3514 
12.01.16)). At a national level, the costs ranged between 32.8 million EUR and 1.2 billion 
EUR (NOK 3.06 milliard and NOK 11.2 milliard). Looking at percentages of national health 
expenditures, the value ranged between 2.1% and 10% (40). A Norwegian estimate from 2010 
calculated that is would be possible to save NOK 800 million per year, by preventing and 
treating malnutrition in Norwegian hospitals. This would represent about 1% of the costs in 
specialized health care (41).  
 
1.5.2 Norwegian hospital financing 
Norwegian hospitals are divided into four health regions with regional hospitals responsible 
for ensuring the population specialized health care. The state owns and finances the regional 
hospitals (42).    
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Performance-based financing (PBF) was introduced for somatic specialized health care 
services 1. July in 1997. The financing of the regional hospitals is divided into a basic 
allocation and an activity based funding. The size of the basic allocation is determined partly 
by the population of the region and their age, and is independent of the hospitals activity. 
PBF, however, depends on the number of patients receiving treatment and the kind of patient 
and treatment. The basis for calculating the PBF refund is the Diagnosis Related Group 
(DRG) system (43).  
DRG is a patient classification system where hospitalization or outpatient consultations in 
somatic institutions are classified into groups that are medically meaningful and whose 
resources are virtually homogenous.  Based on medical and administrative information about 
the patient, each hospital stay is placed in one DRG. DRG provide a clear description of a 
hospitals activity and the composition of its patients. It carries both medical and financial 
information, and makes it possible to compare different hospitals with different patients. All 
treated patients are classified into 860 different groups, and each DRG is then placed in one of 
26 main diagnostic groups. DRG operates at a population level, and that is why there can be 
quite a broad range of resourced used and activity within the same DRG. For individual 
patients or subgroups, it is common that resource usage is different from the average. DRG 
includes all of the hospital costs, including medical service, management and more. The 
Norwegian version of the DRG system is based on the Nordic system NordDRG. A software 
called Norwegian Patient Classification (NPC) is used to conduct the DRG grouping and 
score the activity data from the hospitals, according to PBF rules.  
It is hospital stays and not ward stays which is the basis for the reimbursement, although it is 
the ward stays that are reported in NPC. After the ward stays are DRG grouped, there is a 
further aggregation of ward admissions to hospital stays. If a patient has been transferred to 
other departments within the same hospital stay, all the ward stays will be merged into one 
hospital stay (43).  
 
 
1.6 Practical uses of coding and reimbursement 
The international classification of diagnoses in specialiced health care, ICD-10 has three 
codes for malnutrition; E.43, E.44, and E.46. The norwegian health authorities have suggested 
new criteria for the use of this coding (27): 
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E.43: Severe malnutrition. 
A patient is defined as severely malnourished if he or she meet at least one of the following 
criteria: 
• 15% unintentional weight loss during the last 3 – 6 months, or more than 5% weight 
loss the last month 
• BMI <16 kg/m2 (> 70 years: BMI <18.5 kg/m2) 
• BMI <18.5 kg/m2 (> 70 years: BMI <20 kg/m2) and a simoultaneous unintentional 
weight loss > 5% during the last 3 months 
• Food intake < a quarter of calculated nutritional needs during the last week 
 
E.44: Moderate malnutrition. 
A patient is defined as moderately malnourished if he or she meet at least one of the following 
criteria: 
• Unintentional weight loss > 10% during the last 3 – 6 months or > 5% during the last 
2 months 
• BMI <18.5 kg/m2 (> 70 years: BMI < 20 kg/m2) 
• BMI <20 kg/m2 (> 70 years: BMI < 22 kg/m2) and a simultaneous weight loss > 5% 
during the last 6 months 
• Food intake < half of the calculated nutritional needs during the last week 
 
E.46: Nutritional risk 
A patient is defined as being in nutritional risk if he or she scores the following: 
• NRS2002: score 3 or more 
• MUST: score >1 
• MNA: score < 11 
• SGA: grade B x 
 
As described earlier the reimbursement is based on the patients diagnoses and LOS, and this 
results in different amounts of reimbursement. Further different main diagnoses give different 
reimbursement for additional diagnoses (bidiagnoser). For some main diagnoses this 
additional reimbursement is minimal, while for others it is substantial. These examples, 
illustrates this, using the code given if the patient is in nutritional risk E.46: 
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J15.9 Unspecified bacterial pneumonia → DRG reimbursement = NOK 9 840 ,- 
J15.9 + E.46 → DRG reimbursement = NOK 20 686 ,- 
 
C90.0 Multiple Myeloma → DRG reimbursement = NOK 23 053 ,- 
C90.0 + E.46 → DRG reimbursement = NOK 40 218 ,- 
 
C92.0 AML → DRG reimbursement = NOK 73 699 ,- 
C92.0 + E.46 → DRG reimbursement = NOK 73 699 ,- 
 
 
1.7 Aims of the study 
The overall purpose of this master thesis was to investigate nutritional practice at the 
haematology ward at Haukeland University Hospital, and these factors economic impact.  
The specific aims were: 
To evaluate if an instructive course on screening and treatment of malnutrition among the 
nurses would improve routines for screening of patients.  
To evaluate if an instructive course on screening and treatment of malnutrition among nurses 
would improve physicians’ routines for coding for malnutrition, and if coding would result in 
an increased DRG reimbursement.  
To evaluate if an instructive course on screening and treatment of malnutrition among nurses 
would reduce length of hospital stay as a result of better nutritional treatment, and to further 







Inclusion criteria were all inpatients at the haematological ward at Haukeland University 
Hospital, that spent 24 hours or more at the ward. Two equal time periods a year apart were 
selected, November 2014 to January 2015, and November 2015 to January 2016.   
If patients had more than one admission during the two periods, the longest stay was chosen, 
to better reflect the wards clinical practise. If two or more stays were of the same length, the 
first stay was chosen. Exclusion criteria were day-care patients, patients included in other 
nutrition studies, pregnant women and patients admitted as either terminal or comatose. In 
addition, patients without a medication curve from the ward and patients without a discharge 
summary were excluded. The patients who did not have a discharge summary were patients 
admitted for suspected DVT. The lists of inpatients at 5N included 449 patients in total. In the 
first period 165 patients were admitted, and 284 patients in the second period. Of the total 
number of inpatients, 147 (33%) patients did not meet the inclusion criteria, and in the final 
analysis 137 patients were included in the first period and 165 patients in the second period.  
 
2.2 Study design 
This study is based on retrospectively and prospectively collected patient information from 
the patient administrative electronic database. A three-month period (Nov. 2014 – Jan. 2015) 
was used as reference, and a second three-month period (Nov. 2015 – Jan. 2016) was included 
to evaluate the impact of an intervention. Two students in clinical nutrition were given access 
to reading and collecting all the data. The information was mainly collected from the 
electronic patient record system DIPS (DIPS ASA, Bodø, Norway), and additional 
information about height and weight was collected from Cytodose (CSAM Health AS, Oslo, 
Norway), an electronic system for managing cytostatic treatment. In the first period, medical 
curves containing information about medications, ONS, EN and PN (referred to as TPN in the 
curves) were handwritten paper curves scanned into DIPS. In the second period a new 
electronic system for registering the same information had been introduced; MEONA 





The primary outcomes in this study were change in clinical practice, and the economic 
benefits of this change. This was measured as the proportion of patients screened, proportion 
of patients receiving a diagnose for malnutrition (E46, E44 or E43), proportion of patients 
receiving nutritional treatment, the use of EN, PN and ONS, and the patients´ LOS. In 
addition, we collected information about the patients’ demographics, diagnosis, treatment 
received, weight and height, and comorbidities. Table 1 presents the variables and their 
defined criteria: 
 
Table 1. Overview of variables and the defined criteria for collected information from the medical 
records.  
Variable Criteria  
Height Height documented in DIPS; in patient records, discharge notes or 
  medical curves. 
Weight Weight documented in DIPS; in patient records, discharge notes or  
  medical curves. 
Diagnose ICD-10 diagnoses collected from the patients discharge notes. 
Length of stay Days at the ward recorded from first day to the day of discharge. 
Cytostatic treatment Recorded as a dichotomous variable; yes or no. 
GVHD Only relevant for the patients receiving allogenic HCT. 
Mucositis Registered if documentation of infection/fungi in the mouth, or    
  stating mucositis in the patient records. 
Diarrhoea If the patient had at least one occurrence during the hospital stay. 
Obstipation   
Nausea/vomiting   
Fasting   
Infection Infections that could potentially influence nutritional status were  
  registered. 
Supplements ONS, enrichment of food, and vitamin and mineral supplements. 
  Potassium and sodium not included. 
Nutritional treatment 
ONS, EN, PN or TNP, registered at least once during the hospital stay. 
Vitamin and mineral supplements not included here. 
Referral to clinical dietician If referred at the haematology ward, but also if receiving follow up during 
  stay at the haematology ward.  
Nutritional plan 
Document describing nutritional treatment planned during the patients 
hospital stay.  
Coding of treatment Recieved a code for malnutrition; E43, E44 or E46.  
 




The intervention was aimed towards the nurses, to improve routines for detecting patients in 
nutritional risk and routines for nutritional treatment. A total of 14, lectures were given to the 
nurses and nursing assistants. The nurses were given the opportunity to influence which 
subjects would be addressed, and the following topics were chosen:  
 
Table 2. Overview of the lectures and topics discussed.  
Sep. 2015 Nutritional screening 
  What the ward cafeterias can offer x 2 
  Implementation of nutritional screening at an oncological ward 
Oct. 2015 Consequenses of malnutrition, nutritional screening and nutrition 
  treatment 
Dec. 2015 Energy- and protein enrichment x 2 
  Nutritional supplements x 2 
  Enteral nutrition an parenteral nutrition x 2 
  The nurses role in nutritional treatment x 2 
 
Some of the lectures were given twice to make sure all the nurses had the chance to attend at least 
one of them. The lecture in October was a 45-minute lecture given by a clinical dietician. The lecture 
on implementation of nutritional screening at an oncology ward was given by a nurse from Oncology 
post 1 at Haukeland University Hospital. The other lectures were 10-minute lectures given by two 
students in clinical nutrition.  
 
The lectures were given at the beginning of the work day. Two nurses at the ward was 
assigned as nutritional contacts, and by this given responsibility for staying up to date on 
current routines and procedures in the hospitals guidelines for nutritional treatment. The 
nutritional contacts were given guidance in the screening for malnutrition (NRS2002), and if 
needed they had the opportunity to receive more guidance on the subject.  All of the nurses 
were also given the opportunity to receive individual guidance in how to use the screening 
tool correctly, but this was not used. The ward attended the World Nutrition Day survey 
19.11.2015, where data on nutritional care, patients’ illnesses, food intake history, appetite 
and weight change was collected. These data were not registered in the patient administrative 
electronic database, and the nurses and nurse assistants did not collect the information. In 
November 2015 (in the second period) the ward attended a point prevalence survey, but these 
results were not registered in the medical records.  
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2.5 Use of oral nutritional supplements, enteral nutrition and parenteral 
nutrition 
To perform an evaluation of costs related to use of ONS, EN and PN, information about 
ordered amounts of these products were collected from the hospital kitchen and the hospital 
pharmacy. Ordered amounts and costs of ONS were added to a total amount per period, and 
further divided by number of patients admitted in the respective periods. The amounts and 
costs were also divided by the amounts used of ONS used as documented in the medical 
records. Ordered amounts and costs of EN and PN were evaluated in the same manner.  
 
 
2.6 Estimation of diagnosis related group (DRG) reimbursement 
An estimation of the potential additional reimbursement was evaluated by looking at the 
patients receiving nutritional treatment and no nutritional diagnosis. The programme 
Norwegian Patient Classification (NPC) (Nirvaco AS, Oslo, Norway) was used to calculate 
the reimbursement the different diagnoses gave. Information about LOS, all patients´ 
diagnoses recorded in the discharge note and procedures carried out during the stay was 
plotted. First the reimbursements were calculated with the true diagnoses, and then the 
reimbursement was calculated again with the addition of the E46 diagnosis.  
 
 
2.7 Estimation of potential reduced costs related to LOS 
An estimation of reduced costs at the haematology ward was conducted based on the number 
of inpatients admitted at the ward in 2015. The point prevalence surveys at the haematology 
ward from 2008 – 2015 were used to estimate the number of patients in nutritional risk. 
Information about hospital costs per day at the haematology ward was calculated by dividing 
the annual budget for inpatients with the average number of hospital days at the haematology 
ward. Expenses related to the physician’s salaries were divided in two, before being included 
in the annual budget, as the physicians work both with inpatients and outpatients. Information 
about the additional costs of initiatives to prevent and treat malnutrition were received from 




The calculation used these assumptions: 
• Average hospital costs per day at the haematology ward: NOK 9 350 ,- in 2015 . 
• Average number of patients admitted at the haematology ward in 2015: 1 303. 
• Median LOS at the haematology ward in 2014: 5 days  
• Patients in risk of malnutrition can reduce LOS with one day, when receiving 
nutritional treatment.  
• An average of 70% of the patients at the haematology ward are in risk of malnutrition. 
 
Costs of initiatives related to prevention and treatment, were calculated by the Norwegian 
Health Authorities in 2008. They used the assumption that 30% of the patients are in risk of 
malnutrition. The following presents the costs per patient per day: 
• Screening for malnutrition (all patients every 5th day): NOK 5 ,- 
• Investigations (30% of the patients every 5th day): NOK 6 ,- 
• Treatment/monitoring (30% of the patients daily): NOK 99 ,- 
• Variable costs (products): NOK 14 ,- 
• Indirect costs (increasing knowledge): NOK 60 ,- 
• Documentation (all patients every 5th day): NOK 6 ,- 
 
 
2.8 Statistical analysis  
SPSS Version 23.0 (SPSS Inc., Chicago, IL, USA) was used for data management and data 
analysis. The statistical evaluation included descriptive analysis, estimations of number of 
patients screened for nutritional risk in both periods and number of patients receiving 
nutritional treatment. The chi-square test was used to test for difference in prevalence of 
categorical variables, and the Mann – Whitney U test was used to test for difference in 
medians of the continuous variables. Categorical variables were reported as prevalence (%) 
and continuous variables as median (min-max). Results were considered significant at a p-
value below 0.05.  
 
2.9 Ethics 
Approval from the Regional Committee for Medical and Health Research Ethics was 
exempted from review. Patients were not asked to give consent, as they were not subject to 





Of the total number of 449 inpatients admitted and discharged in the two periods, 147 (33%) 
patients did not meet the inclusion criteria. In the first period 137 patients were included and 
31 excluded (19%), and in the second period 165 patients were included and 119 excluded 
(42%). Significant differences between the two periods were found in LOS (p = 0,015), 
patients with haematological malignancies (p = 0,001), diagnoses for haematological 
malignancies (p = 0,009), patients receiving chemotherapy (p = 0,041), patients treated with 
allogeneic HCST (p = 0,041), number of patients with diarrhoea (p = 0,020), and patients with 
nausea and vomiting (p = 0,010). The general demographics of the patient population (age, 
gender, marital status, living condition, and BMI) were similar in the two periods. 
Characteristics of the study population are presented in Table 3.  
 
Figure 4. Flow chart of included patients.   
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Table 3. Basic characteristics of the study population. 
 
  All patients Patients (Nov. 2014 - Jan. 2015) Patients (Nov. 2015 - Jan. 2016) P-value 
  n = 302 n = 137 (45%) n = 165 (55%)   
Age (median yrs, min-max) 66 (18-96) 66 (18-95) 67 (20-96) 0.992 
Gender (female/male) 139/163 61/76 78/87 0.634 
Length of stay (median days, min-max) 5 (2-78) 5 (1-78) 4 (2-54) 0.015 
Marital status 
    married/cohabiting 168 (56%) 68 (50%) 100 (61%) 
 single/divorced/widowed 97 (32%) 49 (36%) 48 (29%) 
 unknown 37 (12%) 20 (14%) 17 (10%) 0.153 
Living condition 
    home 280 (93%) 124 (91%) 156 (95%) 
 institution 19 (6%) 11 (8%) 8 (5%) 
 unknown 3 (1%) 2 (1%) 1 (0.6%) 0.431 
BMI 
    BMI admission (mean, SD) 26 (4.9) 26 (4.6) 26.1 (5.2) 0.928 
BMI discharge (mean, SD) 26.1 (4.8) 28.9 (6.5) 25.1 (3.6) 0.059 
BMI cytodose (mean, SD) 25.6 (4.2) 25.9 (4.4) 25.0 (3.8) 0.414 
 
BMI = Body Mass Index. 
P-values are given for t-test for BMI admission, BMI discharge, and BMI cytodose. The Mann-Whitney U test was used for age, length of stay and gender, and 





Of the patients admitted to the haematology ward in the two periods, there was a significant 
difference (p = 0.001) in the number of patients with haematological malignancies. MM 
(C90.0) was the most frequent diagnose in both periods, with 31% of the patients in the first 
period, and 17% in the second (Table 3). The second most frequent diagnose was AML 
(C92.0), with 9% of the patient population in the first period, and 7% in the second. There 
was a significant difference in patients receiving chemotherapy in the two periods (p = 0.041), 
and the number of patients receiving allogenous HCT (p = 0.041) (Table 3). Of the 
comorbidities documented in the medical records, the only statistically different were 
diarrhoea (p = 0.020) and nausea/vomiting (p = 0.010) (Table 3).  
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Table 3. Registered information about the population according to haematological cancer, ICD-10 
codes, treatment and comorbidities. 
 
Allo-HSCT = Allogenic Hematopoietic Stem Cell Transplantation, Auto-HSCT = Autologous 
Hematopoietic Stem Cell Transplantation. P-values are given for the chi-square test (or Fisher’s test if 
cell frequencies <5) for all the categorical variables. 
  Patients (Nov. 2014 - Jan. 2015) Patients (Nov. 2015 - Jan. 2016) P-value 
  n = 137  n = 165    
Haematological cancer 
   Yes  77 (56%) 61 (37%) 
 No 60 (44%) 104 (63%) 0.001 
Diagnosis 
   C53.0 1 (0.7%) 0 
 C82.3 1 (0.7%) 0 
 C83.0 1 (0.7%) 0 
 C83.3 0 1 (0.6%) 
 C88.0 6 (4%) 3 (1.8%) 
 C90.0 42 (31%) 28 (17%) 
 C90.1 0 2 (1.2%) 
 C91.0 2 (1.4%) 4 (2.4%) 
 C91.1 6 (4%) 4 (2.4%) 
 C91.7 0 1 (0.6%) 
 C91.9 1 (0.7%) 0 
 C92.0 12 (9%) 12 (7%) 
 C92.1 2 (1.4%) 0 
 C92.4 2 (1.4%) 2 (1.2%) 
 C92.5 0 1 (0.6%) 
 C92.6 1 (0.7%) 0 
 C92.8 0 1 (0.6%) 
 C93.1 0 1 (0.6%) 
 C94.6 1 (0.7%) 0 
 C94.7 0 1 (0.6%) 0.009 
Treatment 
   Cytostatic treatment 40 (29%) 31 (19%) 0.041 
Radiation 6 (4%) 2 (1.2%) 0.147 
Allo-HSCT 4 (3%) 0 0.041 
Auto-HSCT 9 (6.5%) 7 (4%) 0.443 
Comorbidities 
   GVHD 2 (1.4%) 2 (1.2%) 0.713 
Infection (sepsis + other) 41 (30%) 38 (23%) 0.190 
Diarrhoea 23 (17%) 13 (8%) 0.020 
Nausea/vomiting 38 (28%) 25 (15%) 0.010 
Fasting 22 (16%) 25 (15%) 0.874 
Mucositis 11 (8%) 10 (6%) 0.650 
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3.2 Screening for malnutrition and treatment 
Comparisons of screening and nutritional treatment given are presented in Table 4. There was 
a significant difference in screening of patients after the intervention (p < 0,001). No patients  
were screened in the first period, while 15 (9%) patients were screened in the second period. 
Looking at whether the patients had haematological cancer or not, there was a significant 
difference patients being screened. 12 of the 15 (80%) screened patients had haematological 
cancer, 3 of the 15 (20%) had no haematological cancer. There was no significant difference 
between the two periods when comparing nutritional plan, referral to clinical dietician, use of 
coding for malnutrition, type of nutritional treatment given, and use of supplements.  
 
Table 4. Screening, coding for malnutrition, and nutritional treatment.  
 
ONS = Oral Nutritional Supplements, EN = Enteral Nutrition, PN = Parenteral Nutrition.  




  Patients (Nov. 2014 - Jan. 2015) Patients (Nov. 2015 - Jan. 2016) P-value 
  n = 137  n = 165    
Nutrition 
   Patients screened 0 15 (9%) 0.000 
Received nutritional treatment 18 (13%) 29 (17.6%) 0.340 
Received nutritional plan 2 (1.5%) 0 0.205 
Referral to clinical dietician 3 (2%) 5 (3%) 0.732 
Nutritional diagnosis 8 (5.8%) 12 (7%) 0.651 
E46 5 (3.6%) 4 (2.4%) 
 E44 2 (1.4%) 3 (1.8%) 
 E43 1 (0.7%) 5 (3%) 0.522 
Nutritional treatment 
   PN 9 (6.5%) 12 (7%) 
 EN and PN 2 (1.5%) 1 (0.6%) 
 EN 0 2 (1.2%) 
 None 126 (92%) 150 (91%) 0.647 
Supplements: 
   ONS 3 (2%) 8 (5%) 
 Vitamins and minerals 44 (32%) 49 (30%) 
 More than one supplement 11 (8%) 17 (10%) 






Figure 5. Distribution of haematological cancer in screened patients 
P-value calculated with the Fisher’s test (cell frequencie <5). 
* p < 0,05 
 
 
Ordered amounts of ONS, EN and PN are presented in Table 5. When comparing use divided 
by the number of patients in the respective periods, there seems to be an increase in ordered 
amounts of ONS. 1.3 ONS was ordered per patient in the first period, and 2.27 ONS was 
ordered in the second period. There seems to be no large difference in ordered amounts of PN, 
but EN was not ordered at all in the first period, while in the second period 30 bags of EN was 
ordered. Looking at costs of the different kinds of nutritional treatment, it is obvious that PN 




p = 0.021 
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Table 5. Overview of costs related to treatment of malnutrition.  
Ordered nutritional 
supplements First period (Nov. 2014 - Jan. 2015) Second period (Nov. 2015 - Jan. 2016) 
  n Cost n Cost 
PN 39 kr 37543.80 34 kr 40574.00 
EN 0 kr - 30 kr 1209.10 
ONS 174 kr 2567.00 374 kr 5563.11 
Use calculated per patient1 
    Patients 137 
 
165 
 PN 0.3 kr 274.04 0.21 kr 245.90 
EN 0.0 kr - 0.18 kr 7.33 
ONS 1.3 kr 18.74 2.27 kr 33.72 
Use calculated per patient  
    recievng treatment2 
    ONS 14 kr 183.36 25 kr 222.52 
EN 2 kr - 3 kr 403.03 
PN 10 kr 3754.38 13 kr 3121.08 
 
ONS = Oral Nurtitional Supplements, EN = Enteral Nutrition, PN = Parenteral Nutrition.  
1 Ordered nutritional supplements divided by number of patients admitted  
2 Ordered nutritional supplements divided by the number of patients receiving nutritional treatment 
according to the data collected from the medical records and curves.  
 
 
3.3 Coding for malnutrition 
There was not a significant difference in patients receiving a diagnosis for malnutrition when 
comparing the two periods (p = 0,651). The ICD-10 code, E46 was the most frequent used 
diagnosis in the first period (5 patients), and E43 was the most frequent used in the second 
period (5 patients). Of the 15 patients who were screened for malnutrition, 6 (40%) were 
classified as being in risk of malnutrition with a sore of 3 or more according to the NRS 2002. 
Five of the nine (56%) patients in risk of malnutrition received a diagnosis for malnutrition, 
two received the E46 diagnosis, two received the E44 diagnosis, and one patient got the E43 
diagnosis.  
 
3.4 Diagnosis Related Group-reimbursement 
In total 31 of 47 (66%) patients receiving nutritional treatment, were not coded with a 
diagnosis for malnutrition. In the first period 13 of the 18 (72%) patients receiving nutritional 
treatment, were not coded with a diagnosis for malnutrition. In the second period 18 of the 29 
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(62%) patients receiving nutritional treatment, were not coded with a diagnosis for 
malnutrition. This difference was not statistically significant.   
 
Based on our data, calculated additional DRG-reimbursement was only given to one patient. 
The ICD-10 diagnosis code J15.9 Unspecified bacterial pneumonia gave a reimbursement of 
NOK 16046.00, and with the addition of a E46 diagnosis the reimbursement would have been 
NOK 26805.00, with a loss of reimbursement to the ward of NOK 10759.00.  
 
 
3.5 Costs related to length of stay 
Operating expenses per day at the haematology ward was NOK 9 350 ,- in 2015.  
 
Presumed that 70 % of the patients can reduce LOS with 1 day: 
N patients 912 
Costs for patients in nutritional risk (5 days)  NOK 42 636 000.00  
Costs for patients in nutritional risk (4 days)  NOK 34 108 800.00  
Savings   NOK 8 527 200.00  
 
 
Costs of initiatives: 
 Screening: 1303 x 5 x 5 NOK 
Examination: 1303 x 5 x 6 NOK 
 NOK 32 575.00 
NOK 39 090.00  
Treatment/monitoring: 1303 x 5 x 99 NOK  NOK 644 985.00  
Enrichment (ONS, EN, PN):  1303 x 5 x 14 NOK  NOK 91 210.00  
Increasing knowledge: 1303 x 5 x 60 NOK  NOK 390 900.00  
Documentation: 1303 x 5 x 6 NOK  NOK 39 090.00  
 
 NOK 1 237 850.00  
 
Annual net savings for reducing LOS with one day would be: 






In the present study, the aims were to evaluate the screening routines and nutritional treatment 
at a haematology ward, and further to evaluate if an intervention in the form of an instructive 
course for nurses could improve nutritional practice and have an economic impact. This was 
done by collecting data on screening for malnutrition, nutritional treatment documented in the 
medical records, LOS, coding of diagnoses and treatment. To evaluate economic impact, 
information was also collected about the haematology wards orders of EN, PN and ONS. 
With limited time and recourses, an estimation of possible reduction of costs as a result of 
reduced LOS, was conducted using data from the Norwegian Health Authorities (Appendix 
4).  In the following section I will discuss the results of the study as well as the limitations of 
this study model.  
 
4.1 Preventing and treating hospital malnutrition 
This study showed that screening frequency increased from 0 in the first period to 15 (9%) in 
the second period. This was a statistically significant increase (p < 0,001), but still it is a very 
low number of screened patients when you consider the Norwegian Health Authorities’ 
guidelines for preventing and treating malnutrition. According to these guidelines all patients 
should be screened for malnutrition at admission, and then repeatedly on a weekly basis (27). 
Despite these Norwegian guidelines, and consensus statements of the ESPEN and the 
A.S.P.E.N. on the recommendations and advantages of detecting patients in risk of 
malnutrition, it seems that there is a mismatch between recommended practice and clinical 
practice in hospitals (26, 44). Our findings correspond with previous studies, showing that 
nutritional assessment and interventions to treat malnutrition are not sufficiently applied (45-
47). The study based on point prevalence surveys from Haukeland University Hospital 
showed that screening performance improved from 54 – 77% after implementation of the 
nutritional strategy, but when we look at the raw data on screening performance from 2009 – 
2015, there is no clear trend in improved screening performance (35). The percentage of 
screened patients ranges from 64.8% to 85%, with an average of 74%. The data from Randi J. 
Tangvik’s study are not directly comparable with the raw data we have used, as her study 
used a database which was considerably processed with removed duplication and exclusion of 
unsuitable data. Another study based on the same data, examining the nutritional risk profile 
at Haukeland University Hospital, found that the prevalence of nutritional risk in cancer in the 
lymphoid, hematopoietic and related tissues was 50% (18). According to the raw data from 
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point prevalence surveys conducted at the haematology ward, the percentage of patients in 
nutritional risk of the screened patients ranged from 46,7% to 100%, with an average of 70%. 
Screening performance ranged from 47% to 100%, with the average being 89%, and patients 
in nutritional risk receiving nutritional treatment ranged from 11 to 100%, on average 66%. In 
our limited data on screened patients, six of the 15 (40%) screened patients were classified as 
being in risk of malnutrition. Ten of the 15 (67%) screened patients received nutritional 
treatment according to the medical records, but only five (33%) received an ICD-10 code for 
malnutrition. There seems to be a lack of nutritional awareness, and this is also reflected in 
documentation and coding of malnutrition. The lack of coding may have two important 
consequences, the first one is insufficient surveillance of disease and impact of the patient’s 
health and the second is the lack of economic compensation for the cost of treatment.   
In Danish hospitals the use of a screening tool (NRS2002) in patients with malnutrition was 
poorly documented (48). This was alto the case in another university hospital in Norway, 
where they concluded that undernourished older people are not identified and treated 
properly. They also identified five barriers for the nurses to ensuring adequate nutritional 
care: loneliness in nutritional care, a need for competence, low flexibility in food services, 
system failure in nutritional care, and the neglect of nutritional care (49).  
 
 
4.2 Oral nutritional supplements, enteral and parenteral nutrition 
Our intervention did not include the physicians at the haematology ward, and therefore we did 
not expect any difference in the use of EN and PN (referred to as TPN at the ward). Ordered 
amounts of ONS, EN and PN give an estimate of the demand for the different kinds of 
nutritional treatment. In the first period, no EN was ordered, while in the second 30 Easybags 
(500 ml) were ordered. If this reflects an increased attention to use of EN over PN is 
unknown. Looking at ordered amounts calculated per patient at the ward in the respective 
periods, there seemed to be an increase in ordered ONS (1.3 in the first period vs. 2.27 in the 
second). However, when we look at documented use of nutritional treatment in the medical 
records, there is no significant difference. A limitation with these data are that even if these 
are the ordered amounts in the two periods, we cannot know if they have been used or stored 
for later use. Most likely the numbers will deviate from reality. Of the documented treatments 
given PN was used more frequently than EN in both periods, and ONS more frequently than 
EN and PN. In patients undergoing HCT TPN is largely used because of the gastrointestinal 
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complications presenting during this treatment. Moreover, TPN allows for better modulation 
of fluid, electrolytes and micronutrients, and almost all patients undergoing HCT already have 
a central venous catheter placed (10, 23). In patients undergoing high-dose conditioning and 
autologous HSCT, this treatment is also associated with a reduced nutritional status, quality of 
life and physical activity levels (50). Oral nutritional interventions have been shown to be 
effective in increasing nutritional intake and improving some aspects of quality of life in 
patients with cancer (51).   
 
 
4.3 Economical evaluation 
 
 
4.3.1 Diagnosis Related Group reimbursement 
With limited data on patients in nutritional risk, it was difficult to determine which of the 
patients should have received a diagnosis for malnutrition. An attempt was made to evaluate 
if the patients should have had a nutritional diagnosis based on BMI, food intake and change 
in weight in accordance with NRS 2002, but this was not possible due to lack of information 
in the medical records. As a result of this, the number of patients who should have received an 
ICD-10 code for malnutrition (E43, E44 or E46) was estimated using the assumption that all 
patients receiving nutritional treatment are given this on the basis of being in nutritional risk, 
and because of this should have received a diagnosis for malnutrition. The reason E46 was 
chosen, is because this theoretically would be the most common diagnosis for malnutrition, 
and the fact that the other diagnoses (E43 and E44) resulted in the same additional 
reimbursement, even though these are given to patients with more severe cases of 
malnutrition, and hence would need a more comprehensive treatment whit additional costs. 
Calculated additional DRG-reimbursement was only given to one patient with the ICD-10 
diagnosis code J15.9 Unspecified bacterial pneumonia. In the remaining 46 (98%) patients the 
comorbidity malnutrition made no difference because these patients already had other 
complex comorbidities. The effect of coding in different patient groups may differ, and hence 
the different financial benefit observed (52, 53). In a gastroenterology ward 27% of the coded 
patients gave an increased DRG reimbursement (54). Our data suggests that there might be a 
discrepancy between screening done by the nurses and coding made by physicians. In the first 
period 8 patients received an ICD-10 code for malnutrition although none of them were 
screened. In the second period 12 patients received a code, but only five (42%) of them were 
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screened. This discrepancy is probably a result of physicians’ attitude towards coding in 
general since it has long been considered extra unnecessary workload. This area deserves 
further study.  
 
 
4.3.2 Potential reduced costs related to a reduction in length of stay 
 
Annual savings for reducing LOS with one day was estimated to be NOK 7 289 350.00. This 
estimation is based on several questionable factors. The estimates of costs received from the 
Norwegian Health Authorities are now eight years old, and as a result a bit outdated. These 
estimates are also based on the assumption that 30% of the patient population in the hospital 
are in nutritional risk. At the haematology ward an average of 70% of the screened patients in 
the point prevalence surveys were in risk of malnutrition. With more time and recourses, it 
would be preferable to calculate better suited numbers, to give a more accurate estimate of 
costs. A significant decrease in LOS was observed, from a median of 5 to 4 days (p = 0,015). 
The reasons for this have not been investigated, but it might be a result of a larger number of 
patients with haematological cancer in the first period (56%) compared with the second 
period (37%) (p = 0.001). Previous studies have estimated that it is possible to reduce LOS 
with about 20% in patients diagnosed with and treated for malnutrition (55, 56). This was also 
the assumption used in the Norwegian study estimating a potential reduction of costs of 800 
million NOK annually (41). 
 
 
4.4 Strengths and limitations of the study 
 
The strength of this study is the relatively large study sample included from two 3 month 
periods, which makes this a representative sample of patients from the haematology ward. 
The patients at this ward are often severely ill and under intensive treatment, and as a result 
likely have a decline in nutritional status (10). Taking into consideration the number of 
screened patients in the first period (0 patients), meant that the ward had tremendous potential 
for improvement. Although it was not possible to show an improvement in documented 
treatment and coding for malnutrition by giving lectures to nurses, this study suggests that an 
intervention needs to be more comprehensive to induce change in routines. The study has 
several limitations. It cannot confirm causality given that the study is based on data recorded 
in medical records by nurses and physicians. It cannot give conclusions as to why there was a 
small increase in screening for malnutrition, and it cannot explain the reduction of LOS from 
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the first period to the second period. Due to the nature of the collected data, and sample size 
limitations, it was not possible to conduct multivariate analyses to examine the relationship 
between considered variables. This is because the study was based on the medical records of 
patients admitted to the haematology ward in two time periods, and as a result of this the data 
might include the same patients in both periods. The variables included were also subject to 
multicoliniearity. The true relationship between these factors needs to be clarified with 
interventional studies. The reduction in LOS might be explained by the fact that there were 
more patients with haematological malignancies in the first period (56%) compared with the 
second period (37%). Another limitation is that this study includes patients admitted at the 
ward for only 24 hours or more, and this might limit the chance of patients being screened for 
malnutrition, and given the appropriate treatment. Other studies have suggested a threshold of 
seven days or more (19, 57). Other limitations include the fact that haematology patients 
comprise a small fraction of the population in a hospital, with specialized treatments and 
medical challenges, and because of this the results are not generalizable. But still this study 
contributes with valuable information about screening and nutritional treatment at the 
haematology ward. Another limitation to this study is the fact that there were two students 
collecting the data, and manually plotting them into SPSS. This allows room for mistyping 
and errors. An attempt to limit this confounding factor was done by defining criteria for the 
variables collected, and checking for errors using SPSS. The final limitation is that it is based 
on data collected from the medical records, and therefore reflects the physicians and nurses 
documentation of treatment, not necessarily general practice at the ward.  
 
 
4.5 Future aspects 
Ten years have now gone by since the implementation of the nutritional strategy at Haukeland 
University Hospital, and based on the point prevalence surveys it seems that there are is still 
room for improvement in screening patients and giving nutritional treatment in the whole 
hospital population. Our data suggest that the haematology ward especially need to increase 
their focus on nutrition. Further work should investigate the reasons why there is still a lack of 
routines for preventing and treating malnutrition. The Council of Europe has identified 
common barriers to proper nutritional care in hospitals, and these include clearly defining 
responsibilities, sufficient education, influence the patient, cooperation between various 
health care groups, and involvement from hospital managers (28). These barriers are likely to 




The key findings of this study was the significant increase in screened patients, but no 
significant difference in routines for treating malnutrition and coding for malnutrition, after an 
intervention consisting of guidance and lectures on screening and treatment of malnutrition. 
The lack of significant difference in nutritional treatment between the two time periods 
indicate that a small intervention aimed towards the nurses, with lectures on relevant topics is 
not enough to change documented practice in a ward. These findings suggest that there is still 
room for improvement of nutritional routines at the haematology ward, and that nutrition 
should remain a focus area in the years to come. Better routines for preventing and treating 
malnutrition could potentially lead to a reduction in hospital costs, but our findings did not 
show an increased reimbursement after coding for malnutrition as these patients already had 
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”Alt for mange sykehus- og sykehjemspasienter er underernærte, og de får kun dekket 60 % av sitt 
behov for energi og næringsstoffer under innleggelsen. Det er både et menneskelig og et økonomisk 
problem, dels trekker behandlingen ut, dels lykkes den dårligere” (www.bedremadtilsyke.sst.dk).  
 
Alle individer, friske, syke, unge, gamle har rett til å få et adekvat og tilpasset kosthold i forhold til 
deres alder og (sykdoms) tilstand. I henhold til forskrift om internkontroll i sosial og helsetjenesten § 4 
g, Jf. Lov om helsetjenesten i kommunene § 1-3a, og Forskrift om kvalitet i pleie og 
omsorgstjenestene § 3, skal institusjonene ha rutiner for å ivareta pasientene sine grunnleggende 
fysiologiske behov (herunder ernæring) jf. Prof.dr. juris Aslak Syse(1). Dette er også i tråd med 
Europarådets resolusjon(2) og WHOs globale strategi for kosthold og fysisk aktivitet(3).  
 
Helsetilsynet har nylig avdekket svikt i rutiner for å kartlegge og vurdere beboernes ernæringsstatus på 
sykehjem og hjemmebasert omsorg i Hordaland, Rogaland og Telemark (www.helsetilsynet.no). 
Retningslinjer for veiing ved innkomst blir ikke fulgt og det er avdekket store kunnskapsmangler når 
det gjelder beboernes grunnleggende ernæringsbehov og - tiltak. 
 
En underernært pasient har opp til tre ganger så lang liggetid i institusjon som en velernært pasient 
(tall fra Sveits)(4). Beregninger fra Danmark viser at en døgnpris for en underernært pasient koster i 
gjennomsnitt 22% mer enn døgnprisen for en ikke-underernært pasient (www.sst.dk). 
 
Underernæring koster det norske samfunn milliarder: Gitt en døgnpris på 7800 kr (SINTEF-helse 
2006). Regner vi at 50 000 pasienter (30 % av 164 000) av pasientene har over 1.5 – 3 ganger så lang 
liggetid enn velernærte. Man kan anta at gjennomsnittlig liggetid for velernærte 4 dager, og for 
underernærte vil liggetiden være 1.5- 3 ganger så lang = 2- 8 dager ekstra. Ekstrakostnad for å ha disse 
pasientene i sykehus vil være et sted mellom:  
 
7800 x 2 x 50 000 = 780 millioner   
7800 x 8 x 50 000 = 3,1 milliarder 
 
I Storbritannia har de beregnet kostnadene av sykdomsrelatert underernæring i ulike settinger, liggetid 
og kostnader i forhold til ernæringsprodukter samt komplikasjoner. Behandling av pasienter enten 
moderat eller i høy risiko for underernæring ble estimert i 2003 til å koste Storbritannia mellom 7 og 
10 milliarder Euro (ca 68 milliarder kroner, omregnet til Norske forhold: 68 x 5/60 = 5.6 milliarder 
kroner)(5).  
 
Behovet for en innsats er klar. Politikere, sykehusledere og dem som til daglig står med ansvaret for 
maten og for at pasientene får den, bør derfor i høyere grad sette fokus på maten til de syke. Dette 
gjelder også innen primærhelsetjenesten. Hjemmebaserte tjenester og andre tilbud innen pleie og 




For å minske forekomsten av underernæring må man ha verktøy for å diagnostisere. Det kan man ikke 
ved å bare ”se” pasienten.  
For å forebygge underernæring må man ha to delmål: a) diagnostisering av ernæringsmessig risiko for 
å unngå underernæring, b) fange opp underernærte så tidlig som mulig, for å redusere omfang av 
komplikasjoner som følge av underernæring.  
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Det finnes ingen pålitelige laboratorietester for å diagnostisere ernæringsmessig risiko. Vekt og høyde 
kombinert med vekthistorie (vekttap) og evt. spiseproblem vil avdekke om en person er i 
ernæringsmessig risiko eller ikke. Det finnes en rekke screeningsverktøy og de fleste er en variasjon 
over samme tema (vekt, ufrivillig vekttap, matlyst).   
 
Når en person er vurdert til å være i ernæringsmessig risiko, skal vedkommende ha målrettede tiltak 
med oppfølging. Det kan være alt fra behandling av underliggende årsaker til dårlig matinntak, 
kostholdsråd, tilrettelegging av måltider, mellommåltider, næringsdrikker, sondeernæring og/eller 
intravenøs ernæring.  
 
Diagnostisering og behandling av undererernæring er nå innført som en standard på flere sykehus i 
store deler av den vestlige verden. Sykehusene som har innført dette systemet blir akkreditert for god 
ernæringspraksis, og de har muligheter for å dokumentere hvor mange som er i ernæringsmessig 
risiko, i hvilken grad pasientene blir screenet, hvor mange som får dekket sitt ernæringsbehov o.s.v. 
(www.bedremadtilsyke.sst.dk; www.jointcommission.org )  
 
Kostnadsbesparelser 
Sundhetsstyrelsen og Fødevaredirektoratet i Danmark har nylig gjennomført en kost-nytte analyse av 
ernæringsinnsats til underernærte medisinske og kirurgiske pasienter. Analysen viser at den årlige 
nasjonale besparelsen ved ernæringsinnsats i form av næringsdrikker, sonde- og parenteral ernæring 
på danske sykehus vil beløpe seg fra 0,6 til en milliard danske kroner, hovedsakelig i form færre 
sykehusinfeksjoner, lavere medisinforbruk, mindre matsvinn, færre reoperasjoner og kortere liggetid 
(www.sst.dk).  
 
I Storbritannia har man beregnet kostnad-nytte effekten av systematisk bruk av næringsdrikker på 
pasientgrupper i medisinske og kirurgiske avdelinger i sykehus. Analysen viste at besparelsen var på 
over 800 £ (ca 8000 kroner) per pasient i forhold til liggetid og komplikasjoner(5). I Nederland har 
man beregnet at ekstrakostnadene ved innføring av screening og behandling av underernæring til 
omlag 76 Euro per pasient, for å oppnå en dag kortere liggetid for disse pasientene. Døgnprisen var 
estimert til å koste mellom 337 og 476 Euro (2003 priser) (6)  
 
Studier viser at man kan redusere liggetiden for de som blir diagnostisert og behandlet for 







Man må anta at man har vekt lett tilgjengelig. Gjennomføring av veiing og diagnostisering (tre 
spørsmål) skal utføres innen første døgn. Prosedyren vil kunne ta få minutter, beregnet her til å ta 
gjennomsnittlig 5 minutter per pasient. Sykepleier foretar undersøkelsen. I kostnad utgjør dette: 
(minutter /gitt gjennomsnittslønn for sykepleiere inkl sosiale utgifter 500 000/år, 52 uker/ 35,5 
t/uke/60 minx5) = 22,50 kr. Gitt at man diagnostiserer alle pasientene hver 5. dag. Totalt per pasient 
per dag: 22,5 kr/5 = 5 kr per pasient per dag.   
 
Utredning 
Gitt at gjennomsnitt 30 % av pasientene blir funnet til å være i ernæringsmessig risiko. Disse skal ha 
en ernæringsplan: Dette estimeres til å ta 20 minutter for hver underernært pasient (tilsvarer 
sykepleierlønn på 100 kroner). Ekstrakostnad totalt per pasient = 30 kr. Denne prosedyren 




Postens egne pleiere (helsefagarbeidere, kostombud, primærsykepleier eller ernæringsansvarlige) vil 
kunne stå for hoveddelen (90 %)av ernæringsoppfølgingen på post mens en liten del (10%) henvises 
videre til ernæringsfysiolog, ernæringsteam eller lege/spesialist. Gitt at hver underernært pasient får en 
times oppfølging daglig av pleier (tilsvarer kr 300 i sykepleielønn). 10 % av pasientene får 
konsultasjon av annen instans (ernæringsfysiolog, ernæringsteam) som bruker en time per pasient (600 
kr spesialist/legelønn). 300 kr/ 90 % + 600 kr/10 % =  270 kr + 60 kr = 330 kr.  Ekstrakostnad totalt på 
avdelingen til monitorering fordelt på alle pasienter per dag: 99 kr per pasient.  
 
Variable kostnader (kostnader knyttet til ernæringsprodukter):  
Studier fra Nederland indikerer at fleste (3/4) kun trenger enkle tiltak som tilpasset kosthold 
(konsistens, måltidsordning). Dette utgjør liten eller ingen ekstrakostnad for maten. Omtrent 20 % vil 
trenge spesialprodukter (berikning eller en næringsdrikk) som tilsvarer om lag 75 kr ekstra per dag. En 
liten andel (5 %) vil trenge sondeernæring eller intravenøs ernæring. Sondeernæring koster mellom 
100 og 500 kr /dag og intravenøs ernæring koster mellom 500 og 1000 kr/dag (estimert gjennomsnitt: 
400 kr/dag).  
Kostråd og tilpasset kosthold: 15 kr x 75 % = 11 kr 
Næringsdrikker/spesialprodukter 75 kr x 20 % 15 kr 
Sondeernæring/intravenøs ernæring: 400 kr x 5 % = 20 kr  
Totalt: 46 kr per underernært pasient/dag - fordelt på alle pasientene: 14 kr per pasient. 
 
Indirekte kostnader (kompetanseheving) 
For å gjennomføre diagnostisering og behandling av underernæring trengs kunnskaper og kompetanse 
i alle ledd. Personalet skal få trening i verktøy for å diagnostisere, iverksette og dokumentere 
ernæringsstatus, tiltak og resultat. Det vil være behov for å implementere kunnskap om dette både i 
grunnutdannelsen og interne kurs i rutiner og kompetanseheving på den enkelte institusjon. Hvis man 
tar utgangspunkt i at en sykepleier kan bli tatt ut av tjenesten en time daglig for kompetansehevende 
tiltak vil det tilsvare 300 kr (sykepleielønn); Fordelt på antall pasienter, gitt at pleier har ansvar for 5 




Dokumentasjon i epikrise: 3 min (legelønn 1000000)= 30 kr /fordelt utgift på alle pasienter: 30 kr per 
pasient /5 = 6 kr per pasient per dag 
 
 
Oppsummering kostnad (per pasient per dag):  
 
• Diagnostisering: 5 kr 
• Utredning: 6 kr 
• Behandling: 99 kr 
• Ernæringsprodukter: 14 kr 
• Kompetanse 60 kr 
• Dokumentasjon: 6 kr  
 
 





Studier viser at man kan redusere liggetiden for de som blir diagnostisert og behandlet for 
underernæring med om lag 20 % (tall fra Danmark og Nederland og USA)(6-8). I følge Statistisk 
sentralbyrå er gjennomsnittlig liggetid 5 dager i Norge. Et pasient-liggedøgn i norske sykehus er 
estimert til å koste 7800 kroner (SAMDATA rapport 2006).  
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Gitt at de underernærte pasientene oppnår en dag kortere liggetid på grunn av målrettet 
ernæringsbehandling, vil sykehuset spare 7800/5 x 30 % :  
 
• Sum: 468 kr per pasient per dag  
 
Sum besparelse per pasient per dag: 468- 190 = 278 kr.  
 
Sum kostnad-nytte besparelser per år:  
87196 døgnopphold i somatiske sykehus per år (SAMDATA 2006): x 278 =  
 
= 242 millioner kroner per år 
 
• I dette ligger en frigjøring av 52 500 liggedøgn i løpet av et år  
• Andre økonomiske effekter: Flere pasienter blir diagnostisert og kodet med underernæringskoder 
som gir DRG-poeng.  
• De helsemessige gevinster er ikke beregnet inn, men disse vil gi en økonomisk tilleggsgevinst i 
forhold til blant annet færre komplikasjoner, mindre bruk av medikamenter og antibiotika, færre 
reinnleggelser og bedret  overlevelse (9).   
• Når vekt og vektutvikling er kjent vil det også være lettere å følge med på væskebalanse, dosere 
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